Intellectual Property, COVID-19 Vaccines and Equity: A Public Health and Human Rights Critique




COVID-19 vaccines, Intellectual Property, waiver, public health, human rights law


The debates surrounding Intellectual Property (IP) have opened a front in the geopolitical struggle for COVID-19 vaccine access and distribution.  Specific to vaccine manufacture, one route by which local production can be encouraged in low- to middle-income countries would be to ease IP restrictions by such mechanisms as a temporary waiver under the TRIPS [Trade-Related Aspects of Intellectual Property Rights] agreement.  High-income states have resisted the measure, arguing that IP restrictions for COVID-19 vaccines should remain in place.  Their preference is to provide vaccines to poorer states, notably through the COVAX allocation plan, or through bilateral initiatives where excess vaccines are distributed once local supply needs are met.  It is argued here that retaining such IP restrictions constitutes an international public health risk and a potential breach of human rights in the context of international law.

Author Biography

Binoy Kampmark, RMIT University

Dr. Binoy Kampmark is Senior Lecturer in the School of Global, Urban and Social Studies, is an associate of the Human Securities Program at Royal Roads University, and is a former Commonwealth Scholar at Selwyn College, Cambridge University.


Amnesty International (2021a, May 6). US support for intellectual property protection waiver for COVID-19 Vaccines must spur more countries into action.

BBC News (2021, February 16). New WTO boss warns against vaccine nationalism.

Amnesty International. (2021, July 28). Letter to Justin Trudeau, Re: Canada’s Human Rights Obligations on Global Access to COVID-19 vaccines.

Bollyky, T. J. and Brown, C.P. (2020) The tragedy of vaccine nationalism: only cooperation can end the pandemic. Foreign Affairs, 99, 96-109.

Brownlie, I. (2008) Principles of Public International Law, 7th ed. Oxford, Oxford University Press.

Birnie, P, Boyle, A. & Redgwell, C. (2009). International Law and the Environment, 3rd ed. Oxford, Oxford University Press.

Byanyima, W. (2021, January 29). A global vaccine apartheid is unfolding. People’s lives must come before profit. The Guardian.

Clouse, A. (2020, November 24). Fact check: Moderna vaccine funded by government spending, with notable private donation. USA Today.

Committee on Economic, Social and Cultural Rights (CESCR) (2000). General Comment No. 14: The Right to the Highest Attainable Standard of Health (Art 12).

Council for Trade-Related Aspects of Intellectual Property Rights (2021, May 25). Waiver From Certain Provisions of the TRIPS agreement for the Prevention, Containment and Treatment of COVID-19. Revised Decision Text,IP/C/W/669/Rev.1, World Trade Organization.

Der Spiegel (2021, May 5.) Bundersregiering warnt vor Patentaussetzung für Coronaimpfostoffe.

Elber, S. (2012). Bodies as Battlefields: towards the medicalization of insecurity. International Political Sociology 6: 320-2.

European Parliament. (2021, February 24). Declaration from Members of the European Parliament to urge the Commission and Member States not to block the TRIPS waiver at the WTO and to support global access to COVID-19 vaccines.

Garrison, C. (2004, April 13). Consultant Legal Advisor to WHO, Intellectual Property Rights and Vaccines in Developing Countries, Background paper for WHO workshop.

Gleeson, D. (2021, September 14). Australia has finally backed a plan to let developing countries make cheap COVID-19 vaccines – what matters is what we do next. The Conversation.

Green, A. (2021, March 5). TRIPS waiver tripped up in WTO by ‘third way’. Devex.

Gustin, L.O., Karim, S.A., and Mason Meier, B. (2020) Facilitating access to a COVID-19 vaccine through global health law. Journal of Law and Medical Ethics 48: 622-6.

Han-soo, L. (2019, February 20). Pfizer’s patent barrier foils Korea’s 1st pneumococcal conjugate vaccine. Korea Biomedical Review.

Head, M. (2021, November 30) Omicron Is Here: A Lack of COVID Vaccines Is Party Why. Scientific American.

Houldsworth, A. (2021, February 6). No, IP rights are not the barrier to COVID-19 vaccine supplies. IAM.

Independent Panel for Pandemic Preparedness & Response (2021, May). COVID 19: Make it the Last Pandemic.

International Covenant on Economic, Social and Cultural Rights. (1966, December 16.) Adopted by General Assembly Resolution 2200A (XXI), entry into force 3 January 1976.

International Federation of Pharmaceutical Manufacturers & Associations (2020, December 8). Pharma delivers COVID-19 solutions, but calls for the dilution of intellectual property rights are counterproductive. Press Release.

Karp, P. and Visontay, E. (2021, September 8). Australia to support vaccine waiver after months of pressure from human rights groups. The Guardian,

Kilbride, P. (2021, March 2). US Chamber Statement on Proposed WTO IP Rights Waiver.

Krishnan, V. (2021, November 9). How to End Vaccine Apartheid. Foreign Policy.

Laad, A. (2021, August 23). Vaccine Nationalism, the TRIPS Waiver Proposal and Public International Law. OpinioJuris.

Limon, M. (2021, May 21). Vaccine nationalism: Is US support for vaccine patent waivers a PR stunt? Universal Human Rights Group.

Médecins Sans Frontièrs (2020, November 18). India and South Africa Proposal for WTO waiver from intellectual property protections for COVID-19-related medical technologies. Briefing Document.

Moderna (2021, November 12). Our official statement on intellectual property. Thread. Twitter.

MSF (Médecins Sans Frontières) (2021, September 13). Countries must not let another opportunity slip by to advance the global waiver on overcoming COVID-19 medical-tool monopolies. News and Press Release.

Nawrat, A. (2021, March 15). Exploring the COVID-19 vaccine IP waiver proposal at the WTO. Pharmaceutical Technology.

Radio New Zealand (2021, November 23). Former prime minister Helen Clark chides international community’s pandemic response. New Zealand Herald.

Ruschman, A. S. (2021, November 21). Why Moderna won’t share rights to the COVID-19 vaccine with the government that paid for its development. The Conversation,

Sekala, S., Forman, L, Hodgson, T. (2021). Decolonising human rights: how intellectual property laws result in unequal access to the COVID-19 vaccine. BMJ Global Health 6, e006169.

Sirleaf, M. (2021, December 2). Omicron: The Variant that Vaccine Apartheid Built. Just Security.

Sirleaf, E.J & Clark, H. (2021). Report of the Independent Panel for Pandemic Preparedness and Response: making COVID-19 the last pandemic. The Lancet, vol. 398, 101-3.

Tai, K. (2021, May 5) Office of the United States Trade Representative, Statement.

TRIPS (1994, April 15). Agreement on Trade-Related Aspects of Intellectual Property Rights. Marrakesh Agreement Establishing the World Health Organization. Annex 1C. 1869 U.N.T.S 299, 33 I.L.M 1197.

UN Human Rights Office of the High Commissioner (2021, November 29) States must prioritize health and equality over profits and vaccine hoarding, UN experts say.

United Nations Human Rights Office of the High Commissioner (2020, December 17.) Human Rights and Access to COVID-19 Vaccines. Topics in Focus: Access to COVID-19 Vaccines.

UN Human Rights Office of the High Commissioner. (1978). Human Rights and Access to COVID-19 Vaccines. Declaration of Alma-Ata, September.

UN Committee on Economic, Social and Cultural Rights (2000, August 11). General Comment No. 14: The Right to the Highest Attainable Standard of Health (Art 12 of the Covenant). E/C. 12/2000/4.

Usher, A. D. (2020, December 5). South Africa and India push for COVID-19 patents ban. The Lancet, 396: 1790-1.

World Health Organization. (2018, October 25-28). Declaration of Astana. Global Conference on Primary Health Care, Astana.

World Trade Organization. (2001, November 20). Declaration on the TRIPS agreement and public health.WT/MIN(01)/DEC/2, adopted November 14, 2001.

World Trade Organization (1994, April 15). Marrakesh Agreement Establishing the World Trade Organization.

Wouters, O.J., Shadlen, K.C., Salcher-Konrad, M., et al. (2021). Challenges in ensuring global access to COVID 19 vaccines: production, affordability, allocation, and deployment. Lancet 397: 1023-34.

Yunus M., Donaldson, C., and Perron, Jean-Luc. (2020). COVID-19 Vaccines A Global Common Good. The Lancet,